The Pulse
Hims missed Q1. Stock dropped 13% in a day.
Hims & Hers reported Q1 2026 on May 12. Revenue grew 3.8% to $608.1M against $616.85M expected, and net loss widened to $92M from $50M a year earlier.
Gross margin compressed from 73% to 65%.
The compression is mostly the pivot away from compounded GLP-1 and the cost of running branded fulfillment at scale (Hims shipped over 125,000 Wegovy orders in roughly six weeks).
The headline isn't the miss. The headline is that the public market just priced in what private telehealth has been quietly absorbing for months: branded margins are a different business than compounded margins, and the lifecycle math has to be rebuilt for it.
Ro cut weight-loss plan prices up to 50%.
Ro rolled out an aggressive discount this week: up to 50% off annual weight-loss memberships, with access to branded Wegovy and Zepbound bundled in.
This is a commitment-length play, not a price play. The discount is on the annual plan specifically. Monthly subscribers don't get it.
What that signals: Ro is betting that locking patients into 12-month plans now is worth more than holding margin on month-to-month. Watch the next two earnings calls to see whether annual share actually moves.
FDA proposes excluding semaglutide and tirzepatide from the 503B Bulks List.
In a proposal published in early May, the FDA said it does not see a clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk substances. Public comment closes June 29, 2026.
If finalized, the proposal closes the last major scaled compounding pathway for these molecules. 503A pharmacies can still compound on individualized medical necessity, but not as a route to recurring patient supply.
Translation: the compounding endgame is now on a clock. By the back half of 2026, there’s a chance most telehealth treatment catalogs will need branded as the primary path, with compounded as a clinically-justified exception.
The Deep Dive
Ro just made the annual plan a weapon. Most telehealth brands don't even offer one.
Pull up your treatment page. If you sell GLP-1, hair loss, TRT, or skin, look at the plan menu the patient actually sees.
Most telehealth brands offer one default: monthly. Maybe a quarterly bundle. Almost nobody offers a true annual plan with a meaningful discount and a built-out renewal sequence behind it.
That's a retention infrastructure gap.
The math is straightforward. Patients on a longer plan churn less. Not just because the plan psychologically anchors them, but because the cancellation friction is structurally different. A monthly subscriber cancels on a Sunday afternoon when they're frustrated. An annual subscriber has to think about losing the discount, the unused months, and starting the process over.
Commitment length is the cheapest retention lever in your stack. Almost nobody is using it.
1. Most brands lose the "too expensive" cancellation because they have nowhere to send them.
Pull your cancellation data from the last 90 days. Sort by reason. For most telehealth brands, "too expensive" or "cost" is in the top three.
When the patient selects that reason, what actually happens? In most setups, they get a generic "sorry to see you go" email and the cancellation goes through.
The fix is one branch. Before the cancel completes, offer a plan switch:
Monthly to quarterly at 10% off
Quarterly to annual at 20% off
Same treatment, lower monthly cost, longer commitment
We've seen this single change recover 8 to 12% of cancellation-intent patients across telehealth clients. Takes a day to build.
2. Annual plans rewrite your LTV math, but only if you build them right.
A 12-month plan at 20% off sounds like you're trading margin for retention. Run the math, and it's not.
A monthly subscriber averaging 4.5 months at $200 nets $900 lifetime. An annual subscriber at the equivalent of $160 a month, $1,920 paid upfront, nets $1,920 in month one with a meaningfully higher renewal probability because they've already invested.
The risk is refund liability. The build that makes annual plans safe:
A clear pause-and-restart option (not refund) for clinical reasons
A proration policy for non-clinical cancellations that's fair but not generous
A renewal sequence that starts 60 days before the anniversary, not 7
Without those three, an annual plan is a refund headache. With them, it's the highest-LTV product you sell.
3. Pricing pressure from the duopoly is real. Plan length is one of the few defenses left.
Ro at 50% off annual. Hims margin at 65%. The pricing floor for branded GLP-1 in telehealth keeps moving down.
You can't out-spend Hims on Meta. You can't beat Ro on procurement. What you can do is build a plan structure where your best patients self-select into longer commitments, and your monthly patients have a clear path up the ladder.
The brands that survive the price compression aren't the ones with the lowest monthly price. They're the ones whose patients are already 6, 8, 12 months in by the time the next discount war hits.
Takeaway: Audit your plan structure this week. If you only sell monthly, add a quarterly. If you sell monthly and quarterly, build the annual. Wire the cancellation flow to offer the next-tier-up before the cancel completes. The whole exercise takes a week. The downstream LTV impact compounds for years.
Quick Takes
Read what Hims didn't say.
Hims's Q1 call was minutes of margin talk. Almost nothing about cohort retention, repeat order rates, or 6-month patient curves.
That silence is the data. The public scoreboard for telehealth right now is "branded GLP-1 mix vs gross margin." Retention metrics aren't shown because they aren't yet a number the market wants to underwrite.
In private telehealth, retention is still where the multiple gets built. Track what Hims won't.
The compounding cliff is finally on a clock.
The 503B Bulks List proposal sets a June 29 comment close, with a final decision after. State boards are already moving. Novo and Lilly are sending cease-and-desist letters weekly.
The brands quietly migrating their catalog to branded-first (with compounded as a documented clinical exception) won't be panicking in Q3. The ones still building patient acquisition on a compounded-only funnel will be.
Move the catalog now. The flows you build today are the flows running when the rule lands.
One Thing to Try
Pull your last 90 days of cancellations. Filter to reason equals "too expensive" or "cost."
For each one, check what email actually went out. If it was a generic "sorry to see you go" with no plan-switch offer, that's the easiest save you're leaving on the table.
Build one branch this week. Inside the cancellation flow, offer a switch to the next-tier plan at a real discount. Monthly to quarterly at 10% off. Quarterly to annual at 20% off.
Wire it on the cancellation reason, not on the segment. The plan-switch should only fire when "cost" was selected.
Watch the recovery rate over 30 days. Across our telehealth clients, this branch alone recovers a significant percentage of cost-driven cancellations. Half a day of build for one of the highest-ROI flows you'll ship this quarter.
If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz
Reply to this with your biggest retention challenge. I read and respond to every single one.